Scinai Immunotherapeutics (SCNI)

• Market cap: $2.22M
• 1 day: -4.72%
• 5 days: -11.20%
• 1 month: -18.08%
• 3 months: -33.33%
• 6 months: -35.09%
• Year to date: -35.47%
• 1 year: -21.28%
• 5 years: -98.86%
• 10 years: -95.53%
• Sector: Healthcare
• Industry: Biotechnology

About: Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.

Employees: 31

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 4 [Q4 2024] → 4 (+0) [Q1 2025]

0% less ownership

Funds ownership: 0% [Q4 2024] → 0% (-0%) [Q1 2025]

47% less capital invested

Capital invested by funds: $85.1K [Q4 2024] → $45.2K (-$39.9K) [Q1 2025]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2